



International Journal of Current Research Vol. 11, Issue, 04, pp.3057-3060, April, 2019

DOI: https://doi.org/10.24941/ijcr.34908.04.2019

RESEARCH ARTICLE

COMPREHENSIVE LIPID PROFILE- AN INSIGHT INTO THE SURROGATE BIOCHEMICAL INDICATIONS RELATED TO THE ASSESSMENT OF CORONARY ARTERY DISEASE – A NARRATIVE REVIEW ARTICLE

Siraveni Thirupathi, Chinnaiyan, P. and Sujeetha Chandrababu

Department of General Medicine, Shri Sathya Sai Medical College and Research Institute, Kancheepuram, Tamil Nadu, India

ARTICLE INFO

Article History:

Received 09th January, 2019 Received in revised form 16th February, 2019 Accepted 13th March, 2019 Published online 30th April, 2019

Key Words:

Coronary Artery Disease, Triglycerides, Small Dense Low Density Lipoprotein, High Density Lipoprotein, Atherosclerosis.

ABSTRACT

Coronary artery Disease is widely prevalent across the globe and high level of Cholesterol is the significant and well established single major risk factor associated with Coronary Heart Disease. Risk factors for coronary heart disease include health behaviour like physical activity, diet, weight and smoking and health factors like cholesterol, glucose control and blood pressure. Numerous international studies have been confirming the association of dyslipidemia with Coronary artery Disease in most of the world, coronary heart disease produce immense health, imposes high social, economic and personal burden in the globally. Studies described the use of cholesterol lowering agent decrease the occurrence of coronary heart disease. The current study aimed to describe and identify the biochemical and non conventional biomarker as risk factor in early prediction of coronary heart disease.

*Corresponding author: Olkeba Assefa

Copyright©2019, Siraveni Thirupathi et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Citation: Siraveni Thirupathi, Chinnaiyan, P. and Sujeetha Chandrababu. 2019. "Comprehensive lipid profile- An insight into the surrogate biochemical indications related to the assessment of coronary artery disease - A narrative review article", International Journal of Current Research, 11, (04), 3057-3060.

INTRODUCTION

Cardiovascular disorders (CVDs) are among the most common cause of death globally, hence WHO has called it as "modern epidemic" (Park, 2007). Non-communicable disease remains to be a significant public health problem in India. It is accountable for a major percentage of mortality and morbidity. Demographic alterations, changes in the lifestyle alongside with increased rates of urbanization are the foremost reasons accountable for the tilt towards the non-communicable diseases (Upadhyay, 2012). Atherosclerosis was earlier known to consequence from a passive procedure of fat growth. In fresh studies it is measured to be an active process comprising of active, inflamed and thrombosed cells (Ranjith et al., 2009). Inflammation is the significant method in the mechanism of numerous phases of atherosclerosis which comprises start and succession of atheroma, plaque formation and break and restenosis subsequent angioplasty (Braunwald et al., 2001). 8.14 million deaths were reported worldwide due to coronary artery disease in 2013 (Naghavi et al., 2015)

MATERIALS AND METHODS

We searched for relevant articles on pub med and Google scholar database using the keywords lipid profile in coronary artery disease, LDL, HDL, VLDL, Total cholesterol and small dense LDL in coronary artery disease, those article were published between 1990 to 2018.

The article were written in English and available as free full text were selected for review. Related article (including cohort, descriptive, Cross sectional, randomized controlled trials, interventional, Quantitative and Qualitative studies) were extracted. We have been taken the articles having the criteria which includes Age >40 years and Acute myocardial infarction evidenced by history, physical examination, ECG, Elevated CK-MB, 2D Echocardiography. We have excluded the Patients age below 40years, Individuals with Chronic Liver diseases, diabellitus, familial hypercholesterolemia disorder.

Risk Factors: Research indicated that the risk factors of Coronary artery disease includes high blood pressure, obesity, smoking, diabetes, poor diet, lack of exercise, high blood triglycerides, cholesterol and lipoprotein, hypertension and family history. It's estimated 1/3rd of the United States population has high levels of triglycerides, one of the major risk factor for Coronary artery disease (Schreiner et al., 1993; Kivimäki et al., 2012; Lee et al., 2012). High density lipoprotein has a good protective effect and is associated with lowering the risk of coronary artery disease. Researchers showed that a high triglyceride level can predict Coronary artery disease, which has a high mortality in the Western society (Kannel, 2009). Coronary artery disease being the most common causes of mortality in patients with insulin resistance and essential hypertension (Hedblad et al., 2002). Changing day to day lifestyles and modern medicines can help in preventing coronary artery disease. Researchers showed that high levels of triglycerides and cholesterol can prevent vitamin

E from reaching the tissues that is in need it. Vitamin E has antioxidant action which is important for artery walls, and it plays a major role in reducing the oxidation of the LDL-cholesterol. When Low density lipoprotein is oxidized, then it becomes "stickier," and this promotes the accumulation for plaque, inside the arteries. Researches also suggested, vitamin E may prevent thickening of the blood-vessel walls and helps in free flow of blood and favours a good cardiovascular health (Traber *et al.*, 2001).

Plasma Lipids: Cholesterol and triglycerides are lipids of different types that circulate in the blood. The Calories intakes are converted into triglycerides and are stored as fat, which leads to hypertriglyceridemia. Fat from our body is removed with the help of High-density lipoprotein. Low-density lipoprotein builds up plaque inside artery causing atherosclerosis. Low-density lipoprotein-cholesterol and Highdensity lipoprotein are key factors in the atherosclerotic pathogenesis and coronary artery disease. Increased Lowdensity lipoprotein-cholesterol levels and decreased Highdensity lipoprotein-cholesterol levels are associated with increased risk for coronary artery disease. Using fish oil having omega-3 rich triglycerides, lavender, garlic, niacin, lemongrass and holy basil together with healthy diet and lifestyle modifications can reduce the severity of hypertriglyceridemia (Seo et al., 2000; Qi et al., 2002; Simopoulos, 2002; Qi et al., 2003; Kwak et al., 2012).

Proctical demerits in the diagnosis and prognostic value lipids in cad: Triglycerides, phospholipids and Cholesterol were measured by using enzymatic methods (Raum et al., 2007; Schöttker et al., 2013). Un-esterified cholesterol was measured before hydrolysis by cholesterol esterase. HDL cholesterol measured after precipitation of apolipoprotein -B containing lipoproteins with Na- phosphotungstate plus MgCl2 in the supernatant obtained (Warnick, 19982). Apolipoprotein. A-I and B and lipoprotein(a) was measured by immune turbidimetric assay (Winkelmann et al., 2001). Low-density lipoprotein levels are estimated by the Friedewald formula, (Friedewald, 1972) if the Triglycerides level are <4.5 mmol/l. The contents of Very Low-density lipoprotein, intermediatedensity lipoprotein, Low-density lipoprotein, and Highdensity lipoprotein were measured after ultra-centrifugation in a KBr-NaCl density gradient. The distribution and size of Low-density lipoprotein and High-density lipoprotein particles are determined by 2-20 percent poly-acrylamide linear gradient gel electrophoresis of Sudan Black2 prestained plasma, followed by 1 densitometric scanning at 590nm. (Asztalos et al., 2004; Campos et al., 1992).

Small dense low-density lipoprotein: Many experimental studies showed the atherogenic properties of Small dense Low-density lipoprotein particles. Small dense low-density lipoprotein-cholesterol particles can penetrate easily into the arterial walls because of their small size (Khan et al., 2012; Mikhailidis et al., 2011; Bongard et al., 2013). They have more affinity to proteoglycans in the arterial wall, leading to their prolonged stay in the sub-endothelial space (Koba et al., 2006). Besides, the affinity of Small dense low-density lipoprotein-cholesterol for low-density lipoprotein receptors is lower than larger low-density lipoprotein-cholesterol particles and its clearance is delayed from plasma. Small dense low-density lipoprotein-cholesterol particles are in vitamin E deficient and are more susceptible to oxidization. All the above features describe the increased atherogenicity of small dense

low-density lipoprotein subclasses. Small dense low-density lipoprotein-cholesterol is a important emerging risk factor for coronary artery disease. Small dense low-density lipoprotein-cholesterol is a considering biomarker to predict future cardiovascular events in the secondary prevention of stable coronary artery disease (CAD) (Nishikura *et al.*, 2014).

Difficulty in establishing small density ldl: Triglyceride, High-density lipoprotein-cholesterol and Total-cholesterol were determined by standard enzymatic method. HDL-C was measured after isolation of the HDL supernatant following dextran sulfate magnesium precipitation. LDL-C was calculated by using the Friedewald equation. For the purposes of this study, we used archived plasma samples that had been frozen at -80 °C and never previously thawed for the assessment of direct LDL-C and sdLDL-C by automated standardized enzymatic analysis on a Hitachi 911 autoanalyzer. (Hirano et al., 2005).

Triglyceride, high-density lipoprotein-cholesterol ratio is surrogate marker of small dense ldl: The ratio of Triglyceride and High-density lipoprotein-cholesterol, initially described by Gaziano et al, is an atherogenic index is significantly proved to be a highly independent predictor of myocardial infarction, even stronger than Low-density lipoprotein cholesterol, High-density lipoprotein-cholesterol ratio. The Copenhagen Study was found that triglyceride levels by High-density lipoprotein-cholesterol levels showed highly accurate coronary artery disease.18 High triglycerides and High-density lipoprotein-cholesterol caused to atherosclerosis due to the higher rich triglyceride, very low-density lipoprotein that generates small, dense Low density lipoprotein during lipolysis and exchange of lipids. These accumulated LDL particles forms small dense low density lipoprotein particles in the circulation, which closing the atherogenic circle after undergone catabolism.

RESULTS

Among the all revived articles, Majority of the studies were Low-density lipoprotein having positive correlation, and Low-density lipoprotein, HDL ratio values are significantly correlated, HDL having negative correlation and majority of studies showing there was no correlation of triglyceride with coronary artery disease. New predictors like small dense Low-density lipoprotein having very significant correlation with coronary artery disease.

Conclusion

The finding from current study, most of the patient having significant high levels of Triglycerides and Low density lipoprotein cholesterol even after recovery from Coronary artery disease. Triacyliglycerol levels also significantly increased among the coronary heart disease group from the control group, but were not significant statistically. HDL-C was reduced significantly in the coronary heart disease groups, compared to control groups. The Triglycerides cholesterol, high density lipoprotein cholesterol and Low density lipoprotein cholesterol High density lipoprotein cholesterol ratios were increased significantly in the coronary heart disease groups. Triglycerides and high density lipoprotein cholesterol ratio was a significant surrogative marker for Small dense LDL levels, It may be useful for choose the patients to starts an

earlier and aggressive treatment for prevent the progression atherosclerosis and coronary vascular events.

Financial support and sponsorship: Nil.

Conflicts of interest: There are no conflicts of interest.

Acknowledgement

True gratitude is difficult to express in words: Acknowledgement and celebration are essential to fueling passion, making people feel valid and valuable, and giving them a real sense of progress that makes it all worthwhile. It gives me immense pleasure for me to thank everyone who has helped me during the Course of my study. I would like to express sincere thanks and profound gratitude to Chancellor and Vice Chancellor for granting me permission to carry out this study. I take this opportunity to convey my heartiest gratitude and sincere thanks to Dr. P CHINNAIYAN, M.D. FDGP (USA), FCIP., HOD and Professor, Department of General Medicine and Dr. SUJEETHA CHANDRABABU, M.D, Assistant Professor, Department of general medicine, Shri Sathya Sai Medical College & Research Institute, who with their vast knowledge and professional expertise have provided me able guidance and constant encouragement

REFERENCES

throughout the course of my study.

- Asztalos BF., Cupples LA., Demissie S., Horvath KV., Cox CE., Batista MC., Schaefer EJ.2004. High-density lipoprotein subpopulation profile and coronary heart disease prevalence in male participants of the Framingham Offspring Study. Arteriosclerosis, thrombosis, and vascular biology. Nov 1;24(11):2181-7.
- Bongard V., Dallongeville J., Arveiler D., Ruidavets JB., Amouyel P., Wagner A., Ferrières J. 2013. Attainment of low-density lipoprotein cholesterol target in the French general population according to levels of cardiovascular risk: insights from the MONA LISA study. *Archives of cardiovascular diseases*. Feb 1;106(2):93-102.
- Braunwald E., Fauci AS., Kasper DL., Hauser S.L., Longo DL., Jameson JL. 2001. Harrison's principles of internal medicine. McGraw Hill.
- Campos H., Blijlevens E., Mcnamara JR., Ordovas JM., Posner BM., Wilson PW., Castelli WP., Schaefer EJ. 1992. LDL particle size distribution. Results from the Framingham Offspring Study. Arteriosclerosis and thrombosis: *a journal of vascular biology*. Dec;12(12):1410-9.
- Friedewald WT., Levy RI., Fredrickson DS. 1972. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. *Clinical chemistry*. Jun 1;18(6):499-502.
- Hedblad B., Nilsson P., Engström G., Berglund G., Janzon L. 2002. Insulin resistance in non diabetic subjects is associated with increased incidence of myocardial infarction and death. *Diabetic medicine*. Jun;19(6):470-5.
- Hirano T, Ito Y, Yoshino G. 2005. Measurement of small dense low-density lipoprotein particles. *Journal of atherosclerosis and thrombosis*. 12(2):67-72.
- Kannel WB., Vasan RS. 2009. Triglycerides as vascular risk factors: new epidemiologic insights for current opinion in cardiology. *Current opinion in cardiology*. Jul;24(4):345.

- Khan MS. 2012. Small dense LDL: new marker for cardiovascular risk assessment and its therapeutic inflection. *Biochem Anal Biochem.*, 1(6):1-4.
- Kivimäki M., Nyberg ST., Batty GD., Fransson EI., Heikkilä K., Alfredsson L., Bjorner JB., Borritz M., Burr H., Casini A., Clays E. 2012. Job strain as a risk factor for coronary heart disease: a collaborative meta-analysis of individual participant data. The Lancet. Oct 27;380(9852):1491-7.
- Koba S, Hirano T, Ito Y, Tsunoda F, Yokota Y, Ban Y, Iso Y, Suzuki H, Katagiri T. 2006. Significance of small dense low-density lipoprotein-cholesterol concentrations in relation to the severity of coronary heart diseases. Atherosclerosis. Nov 1;189(1):206-14.
- Kwak SM., Myung SK., Lee YJ., Seo HG. 2012. Korean Meta-analysis Study Group. Efficacy of omega-3 fatty acid supplements (eicosapentaenoic acid and docosahexaenoic acid) in the secondary prevention of cardiovascular disease: a meta-analysis of randomized, double-blind, placebo-controlled trials. *Archives of internal medicine*. May 14;172(9):686-94.
- Lee IM., Shiroma EJ., Lobelo F., Puska P., Blair SN., Katzmarzyk PT. 2012. Lancet Physical Activity Series Working Group. Effect of physical inactivity on major non-communicable diseases worldwide: an analysis of burden of disease and life expectancy. *The lancet*. Jul 21;380(9838):219-29.
- Mikhailidis P., Elisaf D., Rizzo M., Berneis M., Griffin K., Zambon B., Athyros A., de Graaf V., Marz J., Parhofer W.G., Battista Rini K.G. 2011. "European panel on low density lipoprotein (LDL) subclasses": a statement on the pathophysiology, atherogenicity and clinical significance of LDL subclasses. *Current vascular pharmacology*. Sep 1;9(5):533-71.
- Naghavi M., Wang H., Lozano R., Davis A., Liang X., Zhou M., Vollset SE., Ozgoren AA., Abdalla S., Abd-Allah F., Aziz MI. 2015. Global, regional, and national age-sex specific all-cause and cause-specific mortality for 240 causes of death, 1990-2013: a systematic analysis for the Global Burden of Disease Study 2013. Lancet.
- Nishikura T, Koba S, Yokota Y, Hirano T, Tsunoda F, Shoji M, Hamazaki Y, Suzuki H, Itoh Y, Katagiri T, Kobayashi Y. 2014. Elevated small dense low-density lipoprotein cholesterol as a predictor for future cardiovascular events in patients with stable coronary artery disease. *Journal of atherosclerosis and thrombosis*. Aug 26;21(8):755-67.
- Park K. 2007. Epidemiology of chronic non-communicable diseases and conditions. *Park's textbook of preventive and social medicine*.
- Qi K., Al Haideri M., Seo T., Carpentier YA., Deckelbaum RJ. 2003. Effects of particle size on blood clearance and tissue uptake of lipid emulsions with different triglyceride compositions. *Journal of Parenteral and Enteral Nutrition*. Jan;27(1):58-64.
- Qi K., Seo T., Al-Haideri M., Worgall TS., Vogel T., Carpentier YA., Deckelbaum RJ. 2002. Omega-3 triglycerides modify blood clearance and tissue targeting pathways of lipid emulsions. *Biochemistry*. Mar 5;41(9):3119-27.
- Ranjith MP., Divya R., Mehta VK., Krishnan MG., Kamal Raj R., Kavishwar A. 2009. Significance of platelet volume indices and platelet count in ischaemic heart disease. *Journal of clinical pathology*. Sep 1;62(9):830-3.
- Raum E., Rothenbacher D., Löw M., Stegmaier C., Ziegler H., Brenner H. 2007. Changes of cardiovascular risk factors

- and their implications in subsequent birth cohorts of older adults in Germany: a life course approach. *European Journal of Cardiovascular Prevention & Rehabilitation*. Dec;14(6):809-14.
- Schöttker B., Herder C., Rothenbacher D., Roden M., Kolb H., Müller H., Brenner H. 2013. Proinflammatory cytokines, adiponectin, and increased risk of primary cardiovascular events in diabetic patients with or without renal dysfunction: results from the ESTHER study. *Diabetes care*. Jun 1;36(6):1703-11.
- Schreiner PJ., Morrisett JD., Sharrett AR., Patsch W., Tyroler H.A., Wu K., Heiss G. 1993. Lipoprotein [a] as a risk factor for preclinical atherosclerosis. Arteriosclerosis and thrombosis: a journal of vascular biology. Jun;13(6):826-33
- Simopoulos AP. 2002. Omega-3 fatty acids in inflammation and autoimmune diseases. *Journal of the American College of nutrition*. Dec 1;21(6):495-505.
- Seo T., Al-Haideri M., Treskova E., Worgall TS., Kako Y., Goldberg I.J., Deckelbaum RJ. 2000. Lipoprotein lipase-mediated selective uptake from low density lipoprotein

- requires cell surface proteoglycans and is independent of scavenger receptor class B type 1. *Journal of Biological Chemistry*. Sep 29;275(39):30355-62.
- Traber MG. 2001. Does vitamin E decrease heart attack risk? Summary and implications with respect to dietary recommendations. *The Journal of nutrition*. Feb 1;131(2):395S-7S.
- Upadhyay RP. 2012. An overview of the burden of non-communicable diseases in India. *Iranian journal of public health.*, 41(3):1.
- Warnick G., Benderson J., Albers JJ. 1982. Dextran sulfate-Mg2+ precipitation procedure for quantitation of highdensity-lipoprotein cholesterol. *Clinical chemistry*. Jun 1;28(6):1379-88.
- Winkelmann BR., März W., Boehm BO., Zotz R., Hager J., Hellstern P., Senges J. 2001. Rationale and design of the LURIC study-a resource for functional genomics, pharmacogenomics and long-term prognosis of cardiovascular disease. *Pharmacogenomics*. Feb 1;2(1):S1-73.
